Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, covers the month of September 2026. The report was issued on September 1, 2026, to comply with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding total voting rights.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification concerning share capital and voting rights rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the company's issued share capital as of August 31, 2026:
- Total issued shares: 4,316,302,379 Ordinary Shares (31 1/2 pence each).
- Treasury shares held: 270,881,064 Ordinary Shares.
- Total voting rights: 4,045,421,315.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves solely to notify the market of the denominator for shareholder interest calculations under FCA rules.
Important Facts for Investors
- Voting Rights Denominator: Shareholders should use 4,045,421,315 as the total number of voting rights to determine notification thresholds for interest changes.
- Treasury Holdings: Approximately 6.3% of the issued share capital (270,881,064 shares) is held in Treasury and does not carry voting rights.
- Contact for Notifications: Shareholder notifications should be directed to company.secretary@gsk.com.